STRYKER CORP
SYKAPI behind this page
SYK Q3 2025 request
Playground key active
/api/financials?ticker=SYK&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 6,057 | 5,494 | +10.2% |
Show Product Lines breakouts |
|||
| Endoscopy · MedSurg and Neurotechnology: | 743 | 689 | +7.8% |
| Endoscopy · MedSurg and Neurotechnology: | 153 | 148 | +3.4% |
| Endoscopy · MedSurg and Neurotechnology: | 896 | 837 | +7.0% |
| Hips · Orthopaedics: | 279 | 256 | +9.0% |
| Hips · Orthopaedics: | 178 | 164 | +8.5% |
| Hips · Orthopaedics: | 457 | 420 | +8.8% |
| Instruments · MedSurg and Neurotechnology: | 606 | 544 | +11.4% |
| Instruments · MedSurg and Neurotechnology: | 154 | 135 | +14.1% |
| Instruments · MedSurg and Neurotechnology: | 760 | 679 | +11.9% |
| Knees · Orthopaedics: | 452 | 417 | +8.4% |
| Knees · Orthopaedics: | 176 | 153 | +15.0% |
| Knees · Orthopaedics: | 628 | 570 | +10.2% |
| Medical · MedSurg and Neurotechnology: | 827 | 783 | +5.6% |
| Medical · MedSurg and Neurotechnology: | 158 | 155 | +1.9% |
| Medical · MedSurg and Neurotechnology: | 985 | 938 | +5.0% |
| Neuro Cranial · MedSurg and Neurotechnology: | 524 | 448 | +17.0% |
| Neuro Cranial · MedSurg and Neurotechnology: | 113 | 93 | +21.5% |
| Neuro Cranial · MedSurg and Neurotechnology: | 637 | 541 | +17.7% |
| Other · Orthopaedics: | 154 | 111 | +38.7% |
| Other · Orthopaedics: | 49 | 48 | +2.1% |
| Other · Orthopaedics: | 203 | 159 | +27.7% |
| Spinal Implants · Orthopaedics: | 6 | 53 | -88.7% |
| Spinal Implants · Orthopaedics: | 6 | 172 | -96.5% |
| Trauma and Extremities · Orthopaedics: | 703 | 621 | +13.2% |
| Trauma and Extremities · Orthopaedics: | 257 | 228 | +12.7% |
| Trauma and Extremities · Orthopaedics: | 960 | 849 | +13.1% |
| Vascular · MedSurg and Neurotechnology: | 283 | 121 | +133.9% |
| Vascular · MedSurg and Neurotechnology: | 242 | 208 | +16.3% |
| Vascular · MedSurg and Neurotechnology: | 525 | 329 | +59.6% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: | 3,803 | 3,324 | +14.4% |
| MedSurg and Neurotechnology: · Non Us | 820 | 739 | +11.0% |
| MedSurg and Neurotechnology: · Operating Segments | 3,803 | 3,324 | +14.4% |
| MedSurg and Neurotechnology: · US | 2,983 | 2,585 | +15.4% |
| Orthopaedics · Operating Segments | 2,254 | 2,170 | +3.9% |
| Orthopaedics: | 2,254 | 2,170 | +3.9% |
| Orthopaedics: · Non Us | 666 | 646 | +3.1% |
| Orthopaedics: · US | 1,588 | 1,524 | +4.2% |
Show Geography breakouts |
|||
| Non Us | 1,486 | 1,385 | +7.3% |
| US | 4,571 | 4,109 | +11.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 6,057 | 5,494 | +10.2% |
| Cost of Revenue | 2,205 | 1,977 | +11.5% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 1,426 | 1,313 | +8.6% |
| Orthopaedics · Operating Segments | 620 | 561 | +10.5% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -8 | -8 | 0.0% |
| Accumulated Other Comprehensive Income · Reclassification Out Of Accumulated Other Comprehensive Income | -8 | -8 | 0.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,046 | 1,874 | +9.2% |
| Gross Profit | 3,852 | 3,517 | +9.5% |
| Research & Development | 410 | 377 | +8.8% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 247 | 205 | +20.5% |
| Orthopaedics · Operating Segments | 132 | 136 | -2.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 379 | 341 | +11.1% |
| Selling, General & Administrative | 2,045 | 1,894 | +8.0% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 972 | 780 | +24.6% |
| Orthopaedics · Operating Segments | 742 | 760 | -2.4% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,714 | 1,540 | +11.3% |
| Amortization Of Intangible Assets | 189 | 159 | +18.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 189 | 159 | +18.9% |
| Asset Impairment Charges | 73 | 2 | +3550.0% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 73 | 2 | +3550.0% |
| Operating Expenses | 2,717 | 2,432 | +11.7% |
| Operating Income | 1,135 | 1,085 | +4.6% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 1,102 | 966 | +14.1% |
| Orthopaedics · Operating Segments | 649 | 601 | +8.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,751 | 1,567 | +11.7% |
| Non-Operating Income (Expense) | -106 | -42 | -152.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | — | — |
| Accumulated Other Comprehensive Income · Reclassification Out Of Accumulated Other Comprehensive Income | -12 | -8 | -50.0% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -11 | -8 | -37.5% |
| Income Before Taxes | 1,029 | 1,043 | -1.3% |
| Income Tax Expense (Benefit) | 170 | 209 | -18.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | -2 | +50.0% |
| Accumulated Other Comprehensive Income · Reclassification Out Of Accumulated Other Comprehensive Income | -4 | -4 | 0.0% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -3 | -2 | -50.0% |
| Net Income | 859 | 834 | +3.0% |
Show Equity Components breakouts |
|||
| Retained Earnings | 859 | 834 | +3.0% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 1,134 | 1,084 | +4.6% |
| EPS (Basic) | 2.25 | 2.18 | +3.2% |
| EPS (Diluted) | 2.22 | 2.16 | +2.8% |
| Wtd Avg Shares (Basic) | 382.4 | 381.1 | +0.3% |
| Weighted Average Number Diluted Shares Outstanding Adjustment | 4.3 | 4.5 | -4.4% |
| Wtd Avg Shares (Diluted) | 386.7 | 385.6 | +0.3% |
| Common Stock Dividends Per Share Declared | 0.84 | 0.8 | +5.0% |
| Comprehensive Income | 855 | 644 | +32.8% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract | 22 | 36 | -38.9% |
| Foreign Exchange Contract · Cost Of Sales | 8 | 8 | 0.0% |
| Foreign Exchange Contract · Other Nonoperating Income Expense | 3 | 20 | -85.0% |
Show Derivative Instruments Gain Loss By Hedging Relationship breakouts |
|||
| Net Investment Hedging · Other Nonoperating Income Expense | 11 | 8 | +37.5% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 3,256 | 3,850 | -15.4% |
| Available For Sale Securities Debt Securities Current | 87 | 84 | +3.6% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 87 | 84 | +3.6% |
| Fair Value Inputs Level2 · Asset Backed Securities | 50 | 50 | 0.0% |
| Fair Value Inputs Level2 · Certificates Of Deposit | 1 | 5 | -80.0% |
| Fair Value Inputs Level2 · US Treasury Securities | 36 | 28 | +28.6% |
| Accounts Receivable | 3,643 | 3,736 | -2.5% |
| Inventory Raw Materials And Supplies Net Of Reserves | 1,371 | 1,234 | +11.1% |
| Inventory Work In Process Net Of Reserves | 442 | 391 | +13.0% |
| Inventory Finished Goods Net Of Reserves | 3,557 | 3,667 | -3.0% |
| Inventory | 5,370 | 5,292 | +1.5% |
| Prepaid Expense Current | 1,355 | 961 | +41.0% |
| Total Current Assets | 13,711 | 14,673 | -6.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,734 | 3,429 | +8.9% |
| Goodwill | 19,256 | 16,396 | +17.4% |
Show Business Acquisition breakouts |
|||
| Inari | 3,188 | — | — |
| Deferred Tax Assets | 1,374 | 1,562 | -12.0% |
| Other Non-Current Assets | 3,137 | 2,833 | +10.7% |
| Total Assets | 47,057 | — | — |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 27,280 | — | — |
| Orthopaedics · Operating Segments | 18,192 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 1,585 | — | — |
| Operating Segments | 45,472 | — | — |
| Operating Lease Right-of-Use Assets | 539 | 516 | +4.5% |
| Other Assets | |||
| Property Plant And Equipment Gross | 7,405 | 6,889 | +7.5% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 3,671 | 3,460 | +6.1% |
| Intangible Assets Net Excluding Goodwill | 5,845 | 4,940 | +18.3% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,498 | 1,337 | +12.0% |
| Employee Related Liabilities Current | 1,306 | 1,250 | +4.5% |
| Accrued Income Taxes Current | 118 | 394 | -70.1% |
| Dividends Payable Current | 321 | 305 | +5.2% |
| Other Liabilities Current | 2,421 | 2,224 | +8.9% |
| Debt Current | 1,750 | 2,159 | -18.9% |
| Total Current Liabilities | 7,414 | 7,669 | -3.3% |
| Non-Current Liabilities | |||
| Long-Term Debt | 14,845 | 13,325 | +11.4% |
| Accrued Income Taxes Noncurrent | 400 | 368 | +8.7% |
| Other Non-Current Liabilities | 2,613 | 2,322 | +12.5% |
| Total Liabilities | 25,272 | 23,684 | +6.7% |
| Operating Lease Liabilities | 377 | 374 | +0.8% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 38 | 38 | 0.0% |
| Additional Paid In Capital Common Stock | 2,553 | 2,353 | +8.5% |
| Retained Earnings | 19,960 | 18,303 | +9.1% |
| Accumulated Other Comprehensive Income | -766 | — | — |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 21,785 | 20,149 | +8.1% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 6 | -29 | +120.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 42 | 11 | +281.8% |
| Accumulated Other Comprehensive Income | -766 | -545 | -40.6% |
| Accumulated Translation Adjustment | -814 | -527 | -54.5% |
| Additional Paid In Capital | 2,553 | 2,353 | +8.5% |
| Common Stock | 38 | 38 | 0.0% |
| Retained Earnings | 19,960 | 18,303 | +9.1% |
| Total Liabilities & Equity | 47,057 | 43,833 | +7.4% |
| Land Buildings And Improvements Gross | 1,783 | 1,729 | +3.1% |
| Machinery And Equipment Gross | 5,622 | 5,160 | +9.0% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 334 | 319 | +4.7% |
| Stock-Based Compensation | 195 | 184 | +6.0% |
| Sale Of Inventory Stepped Up To Fair Value At Acquisition | 160 | 38 | +321.1% |
| Deferred Income Taxes | 191 | -21 | +1009.5% |
| Change in Accounts Receivable | 524 | 67 | +682.1% |
| Change in Inventory | -373 | -362 | -3.0% |
| Increase Decrease In Accounts Payable Trade | -205 | -203 | -1.0% |
| Increase Decrease In Accrued Liabilities | -78 | -224 | +65.2% |
| Increase Decrease In Accrued Income Taxes Payable | -577 | -236 | -144.5% |
| Increase Decrease In Other Operating Capital Net | -373 | -186 | -100.5% |
| Net Cash from Operations | 2,901 | 2,311 | +25.5% |
| Depreciation & Amortization | 1,154 | 1,080 | +6.9% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 171 | 170 | +0.6% |
| Orthopaedics · Operating Segments | 313 | 325 | -3.7% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 127 | 118 | +7.6% |
| Operating Segments | 484 | 495 | -2.2% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | -4,950 | -1,598 | -209.8% |
| Payments To Acquire Marketable Securities | -32 | -41 | +22.0% |
| Payments For Proceeds From Short Term Investments | 750 | -750 | +200.0% |
| Proceeds From Sale And Maturity Of Marketable Securities | 40 | 40 | 0.0% |
| Capital Expenditures | -493 | -489 | -0.8% |
| Proceeds From Sales Of Business Affiliate And Productive Assets | 165 | — | — |
| Other Investing Activities | -41 | 42 | -197.6% |
| Net Cash from Investing | -4,561 | -2,697 | -69.1% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | 1 | -32 | +103.1% |
| Proceeds From Issuance Of Long Term Debt | 2,979 | 3,011 | -1.1% |
| Repayments Of Long Term Debt | -650 | -601 | -8.2% |
| Payments Of Dividends | -963 | -914 | -5.4% |
| Tax Withholding for Share Compensation | -132 | -146 | +9.6% |
| Proceeds From Payments For Other Financing Activities | -29 | -49 | +40.8% |
| Net Cash from Financing | 1,206 | 1,269 | -5.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 58 | -4 | +1550.0% |
| Net Change in Cash | -396 | 879 | -145.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,256 | 3,850 | -15.4% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.